Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trialYan Zhao, Bo Chen, Furen Zhang et al.|Chinese Medical Journal|2023Cited by 40
Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trialYan Zhao, Jianzhong Zhang, Litao Zhang et al.|Allergy|2024Cited by 30
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasisLin Cai, Jianzhong Zhang, Congjun Jiang et al.|British Journal of Dermatology|2024Cited by 21
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasisYu Chen, Gang Wang, Furen Zhang et al.|International Immunopharmacology|2022Cited by 12
Roles of noncoding RNA in allergic rhinitisXiangkun Zhao, Xicheng Song, Yuteng Yang et al.|International Forum of Allergy & Rhinology|2024Cited by 6